Weekly Administration of Gemcitabine Plus Docetaxel in Patients with Advanced Breast Cancer: A Phase 1 Study

Publisher： Karger

E-ISSN： 1423-0232|62|1|33-38

ISSN： 0030-2414

Source： Oncology, Vol.62, Iss.1, 2002-01, pp. : 33-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase I Study of Weekly Gemcitabine and Docetaxel in Patients with Advanced Cancer: A Hoosier Oncology Group Study

By  

Oncology, Vol. 62, Iss. 4, 2002-07 ,pp. : 299-304

Karger

Access to resources Recommend Favorite

Weekly Docetaxel and Gemcitabine as First-Line Treatment for Metastatic Breast Cancer: Results of a Multicenter Phase II Study

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 438-445

Karger

Access to resources Recommend Favorite

A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 38-45

Karger

Access to resources Recommend Favorite

Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study

By  

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 218-223

Karger

Access to resources Recommend Favorite

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 212-216

Karger

Access to resources Recommend Favorite